The official blog of the Lung Institute.

Is COPD Hereditary?

11 Sep 2015
| Under COPD, Lung Disease | Posted by | 7 Comments
Is COPD Hereditary

The Genetics of COPD

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. Most people develop COPD from a lifetime of smoking cigarettes, but that’s not the case for all sufferers. Some develop COPD through breathing harmful air in the workplace. People who work in coal mines, with sand blasting equipment and in metalworking get what’s called occupational COPD by breathing in the small particles that float in the air. However, these factors do not account for 100 percent of all COPD cases. A tiny percentage of people with COPD are getting it without smoking a single cigarette or working in a harmful environment. This phenomenon has people asking the question, “Is COPD Hereditary?”

Alpha-1 Antitrypsin Deficiency

COPD is inescapable for those that are born with the alpha-1 antitrypsin deficiency.  When a mutation with the SERPINA1 gene occurs, the result is alph-1 antitrypsin deficiency. This causes the alpha-1 antitrypsin protein to not combat the enzyme called neutrophil elastase as it does in the body of a person without the genetic disorder. The result is that white blood cells normally enlisted to fight infections are left unregulated and attack the alveoli, causing sufferers to lose lung capacity and become increasingly short of breath.

The deficiency is typically hereditary. Given the difficulty in detecting the disorder, most people who have the deficiency don’t realize they have developed COPD due to a genetic disorder. People with the alpha-1 antitrypsin typically show symptoms of COPD as early at 20 years old. However, some show no symptoms until their late forties or early fifties.

Smokers and others who regularly breathe in polluted air are at greater risk of developing COPD if they have an alpha-1 antitrypsin deficiency. The combination of airborne toxins and weakened alveoli caused by alpha-1 antitrypsin deficiency accelerate the breakdown of the lungs and speed pulmonary deterioration due to the disease.

Being a genetic disorder, alpha-1 antitrypsin deficiency has very few treatment options and no known cure. However, the corresponding lung disease can be treated.

If you or a loved one are experiencing the symptoms described, contact your physician right away. Various treatment options are available after a diagnosis of COPD. Stem cell therapy  could slow the progression of lung disease. To learn more about treatment options, contact  us or call (800) 729-3065.



  1. Lung Institute

    7 months ago

    Thank you for your message. There is research that indicates that people with a certain genetic predisposition may acquire COPD, though it is a very small percentage. The Lung Institute did a blog discussing heredity and COPD that may be of interest.

    Also, while cigarette smoking is the number one risk factor in the development of COPD, research shows that genes may also play a role and could be responsible for why some people who smoke will develop COPD while others will not.

    Best Regards,

    The Lung Institute

  2. T

    7 months ago

    Did not know COPD WAS actually a genetic issue

  3. Pingback: Lung Institute | COPD Awareness Month

  4. Pingback: Lung Institute |Fact: You Don't Have To Smoke To Have COPD

  5. Pingback: Lung Institute | Alpha-1-Antitrypsin Deficiency

  6. Pingback: Lung Disease: Can I Get COPD If I've Never Smoked?

  7. Pingback: COPD Awareness Month

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.